Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Bristol-Myers Squibb Company (BMY)

68.07   0.39 (0.58%) 03-27 16:00
Open: 68.09 Pre. Close: 67.68
High: 68.82 Low: 68.01
Volume: 6,689,785 Market Cap: 143,172(M)

Technical analysis

as of: 2023-03-27 4:17:49 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 81.08     One year: 84.07
Support: Support1: 65.27    Support2: 54.31
Resistance: Resistance1: 69.42    Resistance2: 71.98
Pivot: 67.05
Moving Average: MA(5): 67.5     MA(20): 67.57
MA(100): 73.41     MA(250): 73.75
MACD: MACD(12,26): -0.9     Signal(9): -1.2
Stochastic oscillator: %K(14,3): 55.1     %D(3): 48.3
RSI: RSI(14): 47.3
52-week: High: 81.44  Low: 65.27
Average Vol(K): 3-Month: 8,141 (K)  10-Days: 8,955 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BMY ] has closed below upper band by 11.0%. Bollinger Bands are 54.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 67.81 - 68.14 68.14 - 68.48
Low: 65.9 - 66.25 66.25 - 66.6
Close: 67.12 - 67.67 67.67 - 68.23

Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Headline News

Mon, 27 Mar 2023
Bristol-Myers Squibb: Nobody Panic! Share Price Stumble Shouldn't ... - Seeking Alpha

Mon, 27 Mar 2023
Bristol Myers Squibb: Unraveling The Complexities Of Valuation - Seeking Alpha

Sun, 26 Mar 2023
Ellsworth Advisors LLC Acquires 1754 Shares of Bristol-Myers ... - MarketBeat

Fri, 24 Mar 2023
Wesbanco Bank Inc. Boosts Stock Holdings in Bristol-Myers Squibb ... - MarketBeat

Wed, 22 Mar 2023
Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer? - Forbes

Wed, 15 Mar 2023
Bristol Myers Squibb Announces Progress Toward Long-Term ... - Bristol-Myers Squibb

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 2,100 (M)
Shares Float 2,100 (M)
% Held by Insiders 0 (%)
% Held by Institutions 78.8 (%)
Shares Short 17,020 (K)
Shares Short P.Month 20,720 (K)

Stock Financials

EPS 2.91
EPS Est Next Qtl 0.79
EPS Est This Year 3
EPS Est Next Year 3.23
Book Value (p.s.) 14.81
Profit Margin (%) 13.7
Operating Margin (%) 21.3
Return on Assets (ttm) 5.9
Return on Equity (ttm) 18.9
Qtrly Rev. Growth -4.9
Gross Profit (p.s.) 17.32
Sales Per Share 21.98
EBITDA (p.s.) 9.6
Qtrly Earnings Growth -11.4
Operating Cash Flow 13,070 (M)
Levered Free Cash Flow 13,830 (M)

Stock Valuations

PE Ratio 23.4
PEG Ratio 2
Price to Book value 4.59
Price to Sales 3.09
Price to Cash Flow 10.94

Stock Dividends

Dividend 0.56
Forward Dividend 0
Dividend Yield 0.8%
Dividend Pay Date 2022-01-31
Ex-Dividend Date 2022-01-05
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.